Li-Fraumeni syndrome: cancer risk assessment and clinical management.
about
Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatricianAutophagy in malignant transformation and cancer progressionHow elephants beat cancerPotential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in HumansComparative oncology: what dogs and other species can teach us about humans with cancerEndometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosisThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaBaseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.Hereditary pancreatic cancer: related syndromes and clinical perspective.Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.Colorectal carcinogenesis--update and perspectives.Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.EPMA position paper in cancer: current overview and future perspectives.Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous nicheTP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.Timing and context: important considerations in the return of genetic results to research participants.Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.Adrenocortical carcinoma with extension to the inferior vena cava and right atrium: 20-month-old girl with TP53 mutationThe Features of Colorectal Tumors in a Patient with Li-Fraumeni Syndrome.Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.The importance of p53 pathway genetics in inherited and somatic cancer genomes.Hereditary breast and ovarian cancer: new genes in confined pathways.Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia.Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.PRMT5-dependent p53 escape in tumorigenesis.PRMT5 is required for lymphomagenesis triggered by multiple oncogenic driversPsychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.Clinical implications of germline mutations in breast cancer: TP53.Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.
P2860
Q26801429-78FC90B2-A665-49E2-A13B-DF066F710985Q27000191-9C6B1CEE-EF75-4763-B423-646E97D3F1A3Q28109325-196673EA-ABDC-4D49-8E9C-F685C052F7AFQ28603196-2FFBD6EE-89E1-44E6-8EDE-1BEA77664BD0Q28607304-643C2104-1520-484F-9D4D-69C948FD1848Q30234614-3700663A-13D7-4477-BFCF-52F6E87CBA61Q30357776-D88FABCE-25DA-4DBB-85A8-1F337F008EC3Q33796552-31A63A70-F715-4548-A283-64C2824BA86EQ33844055-C812B12D-20A7-4DF6-BE14-9C59E3532389Q33851085-A26AD320-D8C0-478F-8082-7AFF86B3FA2EQ33872384-13C45719-05E3-4A12-AB11-1B999071D6F2Q34667352-074E7903-BD32-42C7-9833-FF43F6A6BCCCQ35033429-A8D7D1B9-C733-414D-A160-5D3C60DA9616Q35198383-B8A816A6-6E81-48EE-87D0-37DE3ADFDD10Q35532215-8D2F3C4A-4A57-471C-87C3-5CC0CFE0B089Q35717532-A070621B-1317-4D88-8A7A-6E7E762DC5BEQ35781400-12E4952A-242B-483B-A441-269487475E34Q35920997-5E5D3DAC-38D5-403D-97C5-C102460F8590Q36101775-B7C5241F-0FD0-40AA-AAF6-3F83DD111A51Q36470928-EF11F7C8-6291-48EA-8BD1-215F238FA018Q36821184-C0128299-4029-43C5-BB24-8F2003B42567Q37038312-2F998065-E424-417C-9B9C-FB0DFE9953EBQ37697272-E9012D6E-BC0B-4EC6-B720-5039EAD80526Q37722958-9BE3B673-5864-4338-AEB9-B2451D54E6D5Q38621094-F46F68D3-FBFD-4FD5-B350-0343B786F0E9Q38627916-02FEEDA0-DE8A-4098-9F9B-5E0A6A74042EQ38786667-86B9BB1A-65B6-49D1-8C79-0DAA5E276E3EQ38925408-0342886A-214B-4D40-A4ED-2771B144577EQ39041480-06EFB47E-A6E1-439E-B247-10BCC86139E2Q39047607-13EF780F-A912-4EAB-AA87-811550B36705Q39284496-D3DE2EB1-7CE2-4235-A8D4-41274FB69088Q40378252-92046D3A-0C81-4AEB-9C4D-444AB95639CDQ40551179-6A829131-C67B-4141-A5D5-E76D67BBABDDQ41733541-F744E1DE-4B7B-4564-9909-BDFBA6CC400EQ41893763-FAA2DB06-6849-4AEC-9C11-7AE688E104E3Q42702906-6808075B-875D-4D4B-9BDB-EE5FA16A9D17Q47369258-C41CD128-5834-4796-B3F4-70F8EFBBB93AQ47564553-E707EBA5-803A-482D-9DCC-1E4A2EF1ACCCQ47607437-79755358-F7B4-4084-B0BC-2B975D4D100FQ47742599-D452F269-12B8-401A-A069-34EF406DA45A
P2860
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
@en
type
label
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
@en
prefLabel
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
@en
P2093
P2860
P50
P1476
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
@en
P2093
Emma Killick
Gillian Mitchell
Kate A McBride
Martin H N Tattersall
P2860
P304
P356
10.1038/NRCLINONC.2014.41
P407
P577
2014-03-18T00:00:00Z